The study aimed at clarifying the effect of SGLT2 inhibitor use in patients with heart failure (HF) on HF hospitalizations, mortality, and health status across different subgroups as seen in five randomized controlled trials. The gene discussed is SLC5A2; the disease is hydrops fetalis.